Streamlining Biomanufacturing of Personalised Cancer Immunotherapies with Synthetic DNA
13 October 2025 | By
A Synthetic DNA Approach for Speed, Scale & Flexibility
List view / Grid view
13 October 2025 | By
A Synthetic DNA Approach for Speed, Scale & Flexibility
In this article Dr Raymond Winquist, Oncology Fellow at Alkermes, covers the longstanding research challenges associated with cytokines: IL-12 and IL-18, and their untapped potential in immunotherapy and immuno-oncology.
In this exclusive interview with Dr Paul Moore, Chief Scientific Officer from Zymeworks, we explore the impressive responses of Zymeworks' antibody-drug conjugate ZW191 in FRα-low expressing models, indicating its efficacy in treating various oncology indications.
Scientists have discovered that a vaccinated San Diego resident has produced antibodies that are effective against multiple variants of SARS-CoV-2, including Omicron. The research also identified three antibodies that can neutralise the virus, giving new insights into different binding mechanisms with the SARS-CoV-2 spike protein. The findings could help to…
An increasing number of people worldwide suffer from inflammatory bowel disease (IBD). However, no treatment is effective for all patients. In this article, researchers working on the Algae4IBD project explain how algae may represent a valuable source of prebiotics and new therapeutic agents for IBD and other diseases.
From a database of more than 200,000 high-resolution, three-dimensional images of human induced pluripotent stem cells, researchers have devised a model to quantify cell shape and internal organization. Susanne Rafelski, Deputy Director of the Allen Institute for Cell Science, revealed details of their study to Drug Target Review.
Unleash the power of drug discovery with this FREE ebook supported by Sartorius! Explore the limitless potential of CRISPR applications and single cell sequencing for drug discovery. Access exclusive insights from industry leaders and stay ahead of the curve with the latest trends. Don't miss out on this opportunity to…
Join the prestigious Drug Discovery Article Competition and showcase your work.
Researchers are exploring the potential use of HDAC inhibitors, a group of drugs known for their capability to impede tumour cell division, to reduce the pain and damage associated with sickle cell disease. The drugs have shown initial evidence of reactivating the gene responsible for producing foetal haemoglobin, which cannot…
A recent study from researchers at the University of California examines the BRCA2 gene, which plays a crucial role in repairing damaged DNA, and possible links with increased risk of breast and ovarian cancer.
Drug Target Review’s Taylor Mixides exclusively interviews Neil Thomas, Partner and Head of Healthcare and Life Sciences for EMEA at Infosys Consulting, on personalised precision medicine, its advances, challenges and the future.
This article highlights a new approach to address human genetics, using STING-seq which provides roadmap to identify variants and genes, enabling deeper understanding of the noncoding genome and targets for therapies
This article outlines the development of the first cardiac implant made from graphene, which is thinner than a single strand of hair yet still functions like a classical pacemaker. It melds softly to the heart to simultaneously sense and treat irregular heartbeats, making it ideal for conforming to soft, dynamic…
This article outlines the development of a new type of nanoparticle that can perform gene-editing in the lungs. Scientists from MIT and the University of Massachusetts Medical School have collaborated to create this Ribonucleic acid (RNA) delivery particles, which have the potential to revolutionise the treatment of lung diseases such…
Get ready to dive into the cutting-edge world of hit-to-lead drug discovery. Look no further than our latest FREE ebook, which explores label-free HTL technologies. Featuring the latest research from leading academics and pharmaceutical companies, including GlaxoSmithKline, Rosalind Franklin Institute and Francis Crick Institute.
With advancements in artificial intelligence, precision medicine and gene editing, the field of drug discovery is undergoing a rapid transformation. In this article, Drug Target Review’s Izzy Wood gets the insider knowledge from industry leaders at SLAS 2023, who are experiencing these changes first hand.